A Prospective Cohort Study to Evaluate the Real-world Effectiveness of Bamlanivimab in Participants With Mild-to-moderate COVID-19 at High Risk for Progressing to Severe Illness, With Matched Controls
Latest Information Update: 23 Nov 2021
At a glance
- Drugs Bamlanivimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms BLAZE-5
- Sponsors Eli Lilly and Company
- 02 Jul 2021 Status changed from active, no longer recruiting to completed.
- 07 Jun 2021 Planned End Date changed from 7 Aug 2021 to 29 Aug 2021.
- 07 Jun 2021 Planned primary completion date changed from 7 Jun 2021 to 29 Jun 2021.